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Yuanfang Guan,2 Matthias Kretzler,2 and Anne Davidson1
Objective. To elucidate the molecular mecha-
nisms involved in renal inflammation during the pro-
gression, remission, and relapse of nephritis in murine
lupus models using transcriptome analysis.
Methods. Kidneys from (NZB  NZW)F1 (NZB/
NZW) and NZM2410 mice were harvested at intervals
during the disease course or after remission induction.
Genome-wide expression profiles were obtained from
microarray analysis of perfused kidneys. Real-time
polymerase chain reaction (PCR) analysis for selected
genes was used to validate the microarray data. Com-
parisons between groups using SAM, and unbiased
analysis of the entire data set using singular value
decomposition and self-organizing maps were per-
formed.
Results. Few changes in the renal molecular pro-
file were detected in prenephritic kidneys, but a signif-
icant shift in gene expression, reflecting inflammatory
cell infiltration and complement activation, occurred at
proteinuria onset. Subsequent changes in gene expres-
sion predominantly affected mitochondrial dysfunction
and metabolic stress pathways. Endothelial cell activa-
tion, tissue remodeling, and tubular damage were the
major pathways associated with loss of renal function.
Remission induction reversed most, but not all, of the
inflammatory changes, and progression toward relapse
was associated with recurrence of inflammation, mito-
chondrial dysfunction, and metabolic stress signatures.
Conclusion. Immune cell infiltration and activa-
tion is associated with proteinuria onset and is reversed
by immunosuppressive therapy, but disease progression
is associated with renal hypoxia and metabolic stress.
Optimal therapy for lupus nephritis may therefore need
to target both immune and nonimmune disease mecha-
nisms. In addition, the overlap of a substantial subset of
molecular markers with those expressed in the kidneys
of lupus patients suggests potential new biomarkers and
therapeutic targets.
Lupus nephritis affects 30–70% of patients with
systemic lupus erythematosus (SLE), and its treatment
remains insufficiently effective and excessively toxic (1–
4). Although biomarkers for nephritis are being identi-
fied (5,6), there is still no reliable way of predicting an
impending renal flare or determining which patients will
respond to therapy. Because human renal tissue cannot
be obtained sequentially during remission and relapse,
animal models are often used to study the progression of
lupus nephritis.
Complete histologic remission of proliferative
glomerulonephritis is induced in 80–90% of (NZB 
NZW)F1 (NZB/NZW) mice (7,8) by a combination of
cyclophosphamide (CYC) and the costimulatory antag-
onists CTLA-4Ig and anti-CD40L (triple therapy) (9), or
a combination of CTLA-4Ig with a BAFF antagonist
(ref. 10 and Davidson A: unpublished observations).
Similarly, BAFF-R-Ig induces long-lasting remission of
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nephritis in NZM2410 mice that ordinarily develop
glomerulosclerosis with rapid progression to renal fail-
ure (11). The induced remission does not abrogate renal
immune complex deposition but is associated with de-
creased renal inflammation and preservation of the
glomerular filtration barrier (11,12). Evidence from mul-
tiple murine models confirms that there is a checkpoint
in disease progression between immune complex depo-
sition and the development of renal impairment (13–15).
In this study, we profiled NZB/NZW mouse
kidneys to define the molecular characteristics of ne-
phritis onset and progression, complete remission, and
progression toward relapse. Surprisingly, only a few
changes in the renal gene expression profile were de-
tected after immune complex deposition, but a major
shift in transcripts occurred at proteinuria onset, reflect-
ing the rapid onset of inflammation. Subsequent changes
in gene expression reflected mitochondrial dysfunction
and metabolic stress. Remission induction reversed
much of the inflammatory gene expression pattern, but
during late remission mitochondrial dysfunction and
metabolic stress signatures recurred before proteinuria
onset. In NZM2410 mice, a limited inflammatory signa-
ture arose during remission but was not associated with
renal decline. In both strains, the presence of protein-
uria was closely associated with renal tubular dysfunc-
tion. Our findings suggest that optimal therapy for SLE
nephritis may need to target both immune and nonim-
mune disease mechanisms.
MATERIALS AND METHODS
Mouse models and treatment protocols. Female NZB/
NZW mice (The Jackson Laboratory) were followed up clini-
cally as previously described (9,16,17). Mice with proteinuria of
300 mg/dl on 2 occasions 24–48 hours apart were treated
with a single dose of 50 mg/kg of CYC and 6 doses of 100 g
of CTLA-4Ig and 250 g of anti-CD40L (CD154) (9). Remis-
sion was defined as proteinuria of 30 mg/dl on 2 occasions.
An early remission group was killed 3–4 weeks after remission
induction and had complete histologic remission by light
microscopy, as defined by composite glomerular and tubuloin-
terstitial scores of 2.5, similar to young controls. The late
remission group was killed 5–14 weeks after remission
induction and had composite glomerular and tubulointerstitial
scores of 3.0 (see Supplementary Figure 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38679/abstract) (12). We also in-
duced remission in 30-week-old mice with proteinuria of
100–300 mg/dl using a single dose of adenovirus expressing
TACI-Ig, together with 2 weeks of CTLA-4Ig (100 g 3 times
per week) (10). These mice were killed 15 weeks after remis-
sion induction therapy; their renal scores were similar to those
of mice with disease in late remission.
Twenty-two–week-old NZM2410 mice (Taconic) were
treated with adenovirus expressing BAFF-R-Ig and killed at
30–35 weeks or at 55 weeks of age as previously described (11).
Control mice were killed at sequential disease stages as
previously described (16,17). The ages and mean renal scores
of each group are shown in Supplementary Table 1 (available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38679/abstract).
Analysis of renal tissues. Hematoxylin and eosin–
stained kidney sections were scored for glomerular and inter-
stitial damage using a semiquantitative scale of 0–4 (18). Renal
RNA extraction, complementary DNA (cDNA) synthesis,
hybridization, microarray processing, data normalization, and
filtering were performed as previously described (16,17). Sig-
nificantly regulated genes were analyzed using Genomatix
Pathway System (GePS; www.genomatix.de) and Ingenuity
Pathway Analysis (IPA; www.ingenuity.com) software. Gene
expression data sets are available at GEO accession nos.
GSE49898, GSE32583, and GSE32591.
Identification of coherent expression modules using
self-organizing map (SOM) analysis. To identify the biologic
processes driving coherent expression modules, we used SOM
analysis to extract the fundamental patterns of gene expression
inherent in the serial data sets from NZB/NZW mice (19). The
average expression values across multiple samples were taken
for each gene for each disease stage. To capture the dynamic
trend across different stages, we centered the expression
pattern for each gene across all stages at 0 and then applied
SOM analysis to identify the coherent expression modules
(19). We used IPA software to identify significantly repre-
sented biologic processes.
Identification of major expression patterns using sin-
gular value decomposition (SVD). To detect major expression
responses during disease progression, we applied SVD on the
time course data. SVD is a mainstream technique for analysis
of multivariate time course data to identify orthogonal pat-
terns. It allows us to transform genome-wide expression data
from genes  arrays space to diagonalized “eigengenes” 
“eigenassays” space (20). The eigengenes (also referred to as
patterns) represent orthogonal expression patterns that may be
hidden in the original data (20–22). The top 600 genes in the
dominant pattern for each comparison were further analyzed.
Real-time quantitative polymerase chain reaction
(qPCR). Real-time qPCR analysis of 166 genes was performed
as previously described (12,16,23).
Statistical analysis. The Institute for Genomic Re-
search MultiExperiment Viewer application was used for
statistical analysis of microarray data as previously described
(16,17). Genes undergoing further analyses met the following
criteria: q value 0.05 and absolute value of log2 fold change
0.26. Genes that met the above criteria and whose mean fold
expression changed by 1.5 fold between the nephritic and
remission stages were considered to be reversed with remis-
sion. The qPCR data were scaled to the mean of the young
mice in each strain, given a value of 1. Genes with q value (false
discovery rate) of 0.05 were considered significant (16,17).
Since all pathways in the GePS are derived from Homo sapiens,
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Table 1. Top significantly regulated canonical pathways and molecules in each pathway in mice with new-onset proteinuria versus mice without
proteinuria and in mice with established proteinuria versus mice with new-onset proteinuria, as assessed by IPA*
Pathway P
No. of genes
regulated
No of genes
in pathway Genes
Top pathways of genes regulated in
mice with new-onset proteinuria
versus mice without proteinuria†
Dendritic cell maturation 4.37 109 35 207 B2M, ICAM1, NFKBIE, HLA–DQA1, LTB, HLA–
DRB1, CD83, HLA–DMB, HLA–DQB1, FCGR1A,
EP300, COL1A2, PLCE1, PIK3CG, HLA–B,
COL18A1, STAT1, PLCD4, FCGR3A, HLA–DMA,
TYROBP, FCGR2A, RELB, IKBKE, DDR1, TLR2,
IL33, COL1A1, TLR4, IL18, FCER1G, CD86, IL1B,
IRF8, COL3A1
Altered T cell and B cell signaling
in RA
3.89  107 21 92 TLR1, HLA–DMA, SPP1, CD79B, RELB, HLA–DQA1,
HLA–DRB1, LTB, HLA–DMB, HLA–DQB1,
TNFRSF17, IL33, TLR2, TLR4, IL18, CXCL13,
TGFB1, FCER1G, CD86, IL1B, TNFSF13B
Antigen presentation pathway 3.63  106 11 40 B2M, PSMB9, HLA–DMA, HLA–DQA1, HLA–B,
HLA–DRB1, HLA–DMB, PSMB8, CD74, TAP1,
TAP2
Atherosclerosis signaling 7.08  106 24 136 APOE, VCAM1, ICAM1, CXCR4, PLA2G7, F3,
TNFRSF12A, SELPG, COL1A2, IL33, PLA2G4A,
COL1A1, ITGB2, IL18, CCL2, APOC3, TGFB1, IL1B,
SERPINA1, S100A8, COL18A1, CCR2, ITGA4,
COL3A1
TREM-1 signaling 1.0  105 15 71 ITGB1, TLR1, ICAM1, TYROBP, CD83, STAT3, TLR2,
TLR4, CXCL3, IL18, CCL2, CASP1, CD86, IL1B,
ITGAX
Fc receptor–mediated
phagocytosis in macrophages and
monocytes
1.10  105 21 102 FYN, ARPC1B, FCGR2A, ACTB, ACTA2, ARPC5,
FCGR1A, PRKCZ, PLD4, HMOX1, ARF6, NCF1,
ACTR3, PIK3CG, ARPC2, HCK, VAMP3, LYN,
ARPC3, FCGR3A, PRKCB
Communication between innate and
adaptive immune cells
1.10  105 17 109 B2M, TLR1, HLA–DRB1, CD83, CCL5, TNFRSF17,
IL33, CXCL10, TLR2, TLR4, IL18, FCER1G, HLA–B,
CD86, CCL3L1/CCL3L3, IL1B, TNFSF13B
Complement system 1.23  105 10 35 C1R, SERPING1, C3, C1S, CFI, C1QC, C1QA, C1QB,
CFH, C3AR1
CD28 signaling in T helper cells 1.4  105 23 132 HLA–DMA, FYN, PTPN6, ARPC1B, NFATC3,
NFKBIE, MAP3K1, ARPC5, HLA–DQA1,
HLA–DRB1, PTPRC, CD3G, FOS, JUN, ACTR3,
PIK3CG, ARPC2, FCER1G, CD86, ARPC3
Cell cycle control of chromosomal
replication
1.86  105 10 31 MCM5, MCM3, MCM6, MCM2, CDT1, ORC6,
CHECK2, MCM4, DBF4, MCM7
Top pathways of genes regulated in
mice with established proteinuria
versus mice with new-onset of
proteinuria‡
TCA cycle II (eukaryotic) 1.48  1010 9 41 SUCLA2, CS, SUCLG1, SDHD, IDH3A, MDH1,
MDH2, ACO1, IDH3B
Mitochondrial dysfunction 4.90  106 13 186 COX6B1, NDUFA9, COX6A1, COX11, SOD2, ATP5B,
COX5A, NDUFB6, SDHD, CYC1, ATP5G3,
NDUFA8, COX15
Inosine-5-phosphate biosynthesis II 1.26 103 2 16 ADSL, PAICS
Arsenate detoxification I
(glutaredoxin)
2.51  103 2 20 AS3MT, GSTO1
Aspartate degradation II 8.32 103 2 14 MDH1, MDH2
* IPA  Ingenuity Pathway Analysis; RA  rheumatoid arthritis; TREM-1  triggering receptor expressed on myeloid cells; TCA  tricarboxylic
acid.
† Top 10 pathways of the 1,342 genes that were regulated in 23-week-old mice with new-onset proteinuria versus 23-week-old mice without
proteinuria (corresponding to 1,194 human gene IDs).
‡ Top 5 pathways of the 321 genes that were regulated in 36-week-old mice with established proteinuria versus 23-week-old mice with new-onset
proteinuria (corresponding to 311 human gene IDs).
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the mouse gene IDs were converted to the corresponding
human orthologs using the NCBI homolog (build 67) for all
GePS and IPA analyses.
The comparisons shown in Supplementary Table 1
(available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38679/abstract) were
performed using Mann-Whitney test. P values less than or
equal to 0.05 were considered significant.
RESULTS
Gene expression profile associated with disease
onset. Only 180 changes in gene expression were found
between 16-week-old mice and 23-week-old mice with-
out proteinuria. The major signature was for immuno-
globulin genes and B cells (see Supplementary Table 2A,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38679/
abstract). Indeed, small lymphoid aggregates containing
plasma cells are found in the renal pelvis of 23-week-old
old NZB/NZW mice (results not shown). Other path-
ways included nitrogen metabolism and fatty acid syn-
thesis.
Similarly, only 109 genes were regulated between
23-week-old mice and 30-week-old mice without pro-
teinuria, reflecting innate immune cell activation, com-
plement protein production, early tubular involvement,
and collagen gene expression (see Supplementary Table
2B, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38679/
abstract). In contrast, major shifts in gene expression
were observed when 23-week-old mice without protein-
uria were compared with 23-week-old mice with new-
onset proteinuria (1,342 genes regulated) (see Supple-
mentary Table 2C). IPA indicated that immune
activation accounted for the top 10 pathways (Table 1).
Figure 1. Patterns of gene expression in (NZB  NZW)F1 (NZB/NZW) mice. A, Diagram showing the numbers of genes regulated between the
indicated stages of disease progression. Dominant pathologic processes identified by Ingenuity Pathway Analysis are shown for each disease stage.
Numbers shown in brackets are the number of human orthologs. B, Diagram showing the numbers of genes regulated between the indicated stages
before (black) and after (green) remission induction. The Venn diagram shows that 654 genes were regulated both during proteinuria onset and
remission. C, Self-organizing map of data sets from each of the disease stages shown in D. The number of dots in each module reflects the number
of genes regulated, and the color reflects the degree of change, either up (orange to red, with red reflecting the most change [cluster 1]) or down
(white to beige, with beige reflecting the most change [cluster 2]) or unchanged (blue). D, Average gene expression for each data set in 3
representative modules (modules 1,7; 3,4; and 7,1). Data sets were from 16-week-old mice, 23-week-old mice without proteinuria (23w NP),
30-week-old mice without proteinuria, 23-week-old mice with proteinuria (23w P), 36–40-week-old mice; mice with disease in early remission treated
with triple therapy (cyclophosphamide [CYC], CTLA-4Ig, and anti-CD40L; early R triple), mice with disease in late remission treated with triple
therapy, and mice with disease in late remission treated with CTLA-4Ig and TACI-Ig (Late R C/T).
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Tubular damage was exemplified by increased expres-
sion of LCN2, FN1, and VIM. Further up-regulation of
several collagen genes indicated early interstitial fibrosis.
Gene expression profile associated with disease
progression. There were 321 gene differences between
the kidneys of 23-week-old old mice with new-onset
proteinuria and those of older mice with established
proteinuria of 2 weeks’ duration; these, surprisingly,
were all down-regulated (see Supplementary Table 2D,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38679/
abstract). IPA indicated that the top 5 pathways involved
metabolic alterations and mitochondrial dysfunction
(Table 1).
Major changes in gene expression were observed
between 30-week-old mice without proteinuria and 36-
week-old mice with established proteinuria (see Supple-
mentary Table 2E, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38679/abstract). The 427 up-regulated genes
reflected inflammation, similar to the pattern observed
at disease onset (see Supplementary Table 3A, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38679/abstract).
The 1,356 down-regulated genes reflected metabolic and
mitochondrial dysfunction, as observed during the pro-
gression of nephritis from onset to established disease
(see Supplementary Table 3B). Gene expression
changes during disease onset and progression are sum-
marized in Figure 1A.
Transcriptional indicators of disease remission.
To identify mechanisms of remission and transcriptional
indicators of renal clinical status, we identified genes
whose expression changed at proteinuria onset and
reversed upon remission. Of the 1,342 genes that were
up-regulated at proteinuria onset, 654 (48.7%) reversed,
603 by 1.5 fold, during complete remission (Figure
1B). (Also see Supplementary Table 2F, available on
the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38679/abstract.) These
genes reflected inflammatory cell infiltration, comple-
ment activity, endothelial cell activation, and extracellu-
lar matrix formation (Table 2 and Supplementary Figure
2A, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38679/
abstract). To determine the relevance to human disease,
we interrogated data sets of genes up-regulated in the
glomeruli and tubulointerstitium of SLE nephritis bi-
Table 2. Top significantly regulated canonical pathways and molecules in each pathway for the 654 genes that were up-regulated in mice at onset
of proteinuria and reversed upon remission, as assessed by IPA*
Pathway P
No. of genes
regulated
No of genes
in pathway Genes
Dendritic cell maturation 6.31  108 22 185 B2M, ICAM1, TYROBP, FCG2RA, RELB, NFKBIE, HLA–DQA1,
IKBKE, CD83, FCGR1A, COL1A2, IL33, TLR2, TLR4, IL18,
PIK3CG, HLA–DRA, CD86, IL1B, IRF8, STAT1, HLA–C
Communication between innate
and adaptive immune cells
1.38  107 15 109 B2M, CD83, CCL5, CCL9, IL33, CXCL10, TLR2, TLR4, IL18,
HLA–DRA, IL1B, TLR13, CD86, TNFSF13B, HLA–C
Cell cycle control of chromosomal
replication
9.77  107 9 31 MCM5, MCM3, MCM6, MCM2, CDT1, ORC6, MCM4, DBF4,
MCM7
TREM-1 signaling 6.03  106 11 66 TLR2, TLR4, IL18, ICAM1, CCL2, TYROBP, CASP1, TLR3,
CD86, IL1B, CD83
Hepatic fibrosis/hepatic stellate
cell activation
2.29  105 18 147 CCR5, VCAM1, ICAM1, FN1, CTGF, MMP2, CCL5, COL1A2,
MYL9, CXCL3, TLR4, LY96, CCL2, IL10RA, CD14, IL1B,
STAT1, PDGFRB
MSP-Ron signaling pathway 7.41  105 9 51 TLR2, CSF2RB, ITGB2, TLR4, KLK3, CCL2, PIK3CG, ACTB,
CCR2
Complement system 7.76  105 7 35 C1R, SERPING1, C3, C1S, C1QA, C1QB, CFH
Altered T cell and B cell signaling
in RA
1.17  104 12 92 IL33, TLR2, TLR4, IL18, SPP1, RELB, HLA–DRA, HLA–DQA1,
TLR13, CD86, IL1B, TNFSF13B
Role of hypercytokinemia/
hyperchemokinemia in the
pathogenesis of influenza
1.32  104 7 44 IL33, CXCL10, IL18, CCR5, CCL2, IL1B, CCL5
Role of pattern recognition
receptors in recognition of
bacteria and viruses
1.58  104 13 106 C3, C1QA, C1QB, CCL5, TLR2, IFIH1, TLR4, CLEC7A, IRF7,
PI3CG, CASP1, IL1B, CLEC6A
* The top 10 pathways of the 654 genes that were up-regulated in mice at onset of proteinuria and reversed upon remission (corresponding to 587
human gene IDs) are shown. MSP  macrophage-signaling pathway (see Table 1 for definitions).
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Table 3. Top 5 canonical pathways significantly regulated for the genes in each module of the SOM
analysis, as assessed by IPA*
Module Pathway P
Cluster 1 (915 genes)
1_6 IL-12 signaling and production in macrophages 1.58  106
1_6 Prolactin signaling 7.59  105
1_6 PKC signaling in T lymphocytes 8.32  105
1_6 CTLA-4 signaling in cytotoxic T lymphocytes 1.17  104
1_6 Granulocyte adhesion and diapedesis 9.33 105
1_7 Granulocyte adhesion and diapedesis 1.58 1012
1_7 Altered T cell and B cell signaling in RA 1.26  1013
1_7 Dendritic cell maturation 2.00  1013
1_7 Agranulocyte adhesion and diapedesis 3.09 1010
1_7 Communication between innate and adaptive immune cells 4.90 1010
2_6 Semaphorin signaling in neurons 7.59  106
2_6 Toll-like receptor signaling 8.51  106
2_6 Tec kinase signaling 8.91  106
2_6 LXR/RXR activation 6.76 105
2_6 CD28 signaling in T helper cells 6.76  105
2_7 Cell cycle control of chromosomal replication 5.37  105
2_7 Role of IL-17A in psoriasis 2.29  103
2_7 Estrogen-mediated S-phase entry 1.62 102
2_7 p53 signaling 3.39 102
2_7 Adenine and adenosine salvage III 3.98  102
3_7 Mitotic roles of polo-like kinase 2.24  104
3_7 G signaling 1.41  10
3
3_7 Chemokine signaling 2.34  103
3_7 HGF signaling 2.51 103
3_7 fMLP signaling in neutrophils 3.39  103
Cluster 2 (1,728 genes)
5_1 Catecholamine biosynthesis 2.88 105
5_1 Mineralocorticoid biosynthesis 1.26 102
5_1 Noradrenaline and adrenaline degradation 1.51 102
5_1 Glucocorticoid biosynthesis 1.55 102
5_1 VDR/RXR activation 1.55 102
6_1 Flavin biosynthesis IV (mammalian) 1.58 104
6_1 Tryptophan degradation X (mammalian, via tryptamine) 9.55 104
6_1 Glutathione-mediated detoxification 2.88 103
6_1 Glycogen degradation II 4.17  103
6_1 Ethanol degradation II 4.07  103
7_1 Ethanol degradation II 3.98  107
6_2 Heme biosynthesis II 2.34  104
6_2 Tetrapyrrole biosynthesis II 2.04  103
6_2 Sphingomyelin metabolism 4.17 103
6_2 Ubiquinol-10 biosynthesis (eukaryotic) 1.05 102
6_2 Mitochondrial dysfunction 1.38 102
7_2 Mitochondrial dysfunction 1.26 1013
7_3 Mitochondrial dysfunction 5.01 1015
7_1 Glycine betaine degradation 9.77 108
7_1 Nicotine degradation II 3.24  107
7_1 Superpathway of methionine degradation 1.35 106
7_1 Serotonin degradation 1.74 106
7_2 TCA cycle II (eukaryotic) 1.48  108
7_2 Valine degradation I 1.26  104
7_2 Branched-chain -keto acid dehydrogenase complex 1.32  103
7_2 Fatty acid -oxidation I 8.51  104
7_3 Fatty acid -oxidation I 1.86  103
7_3 L-glutamine biosynthesis II (tRNA-dependent) 3.39 104
7_3 Coenzyme A biosynthesis 1.00 103
7_3 Stearate biosynthesis I (animals) 3.02  103
* SOM  self-organizing map; IPA  Ingenuity Pathway Analysis; IL-12  interleukin-12; PKC 
protein kinase C; RA  rheumatoid arthritis; LXR  liver X receptor; RXR  retinoid X receptor;
HGF  hepatocyte growth factor; VDR  vitamin D receptor; TCA  tricarboxylic acid; tRNA 
transfer RNA.
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opsy specimens compared with normal control biopsy
specimens (17). A striking level of concordance was
observed. Of the 654 mouse marker genes (correspond-
ing to 587 human genes), 175 were concordantly regu-
lated in both glomeruli and tubules of SLE nephritis
biopsy specimens (see Supplementary Table 4A, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38679/abstract),
and a further 145 were concordantly regulated in one
of the two compartments (Supplementary Table 4B).
GePS analysis of the 175 shared genes revealed several
nodes of pathogenic significance (Supplementary Figure
2B), including CD14 and CD18 (mononuclear cell
infiltration/activation), CD44 (cell migration), Fn1 (extra-
cellular matrix and fibrosis), CXCL10, CCL5, IL18
(chemokines/cytokines), and Stat1 (type I interferon
[IFN] pathway). Stat1 was the most represented tran-
scription factor; 54 of the 175 genes had a Stat1 binding
site in their promoter (Supplementary Table 4C). Ig
transcripts, CXCL13, and ITGAM were not completely
down-regulated during remission, consistent with the
persistence of small inflammatory infiltrates.
Gene expression profile associated with progres-
sion toward relapse. Only 39 differences were observed
between early and late remission after triple therapy (see
Supplementary Table 2G, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38679/abstract). In contrast, 403 gene
differences were noted between early remission and
late remission after CTLA4-Ig/TACI-Ig treatment, and
all were down-regulated and involved metabolic path-
ways (Supplementary Table 2H). Compared with mice
studied late after triple therapy, mice with established
proteinuria had 174 up-regulated genes and 41 down-
regulated genes (Supplementary Table 2I). Only a few
differences were observed between mice with estab-
lished proteinuria and CTLA4-Ig/TACI-Ig–treated
mice, confirming that these mice represent a later stage
in the progressive relapse process. Gene expression
changes during nephritis and early and late remission
are summarized in Figure 1B.
Confirmation using SOM analysis. To identify
genes that changed coherently throughout disease pro-
gression and remission, we applied SOM analysis, an
unbiased approach to clustering genes based on the
similarity between their sequential expression profiles.
Figure 1C displays the SOM for this study. In the SOM
panel, the top right set of modules (cluster 1, containing
modules 1,6/1,7/2,6/2,7/3,7) includes mostly proinflam-
matory genes with coherent expression throughout the
study. In contrast, the bottom left set of modules (cluster
2, containing modules 5,1/6,1/6,2/7,1/7,2/7,3) is enriched
for genes associated with metabolic stress and mitochon-
drial dysfunction (see Supplementary Table 5, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38679/abstract).
Representative modules are shown in Figure 1D. IPA
analysis of clusters 1 and 2 is shown in Table 3. Notably,
426 of the 1,098 mitochondrial genes in the mouse
MitoCarta database were represented in cluster 2. Of
these, 98 (23%) were significantly regulated in the
kidneys of mice with disease in late remission after
treatment with CTLA-4Ig and TACI-Ig compared with
mice with disease in early remission (Figure 2). In
addition, of 197 selected genes representing mouse
hypoxia, cellular stress and toxicity, and oxidative stress
(SABiosciences), 34 were represented in cluster 2 (Fig-
ure 2); of these, 8 (23.5%) were significantly regulated in
the kidneys of mice with disease in late remission after
combination treatment with CTLA-4Ig and TACI-Ig
compared with mice with disease in early remission.
Unbiased identification of biomarkers of disease
onset, progression, and remission. A second unbiased
approach to biomarker identification was to apply an
SVD method to the sequential NZB/NZW data sets.
This analysis identified genes that were most tightly
regulated during changes in disease stage and was
performed without consideration of actual fold change
in gene expression. Of the top 300 positively and 300
negatively regulated genes within the dominant pattern
(see Supplementary Figure 3A, available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.38679/abstract), 554 with human
homologs were differentially expressed between 16-
week-old prenephritic mice and 36-week-old mice with
proteinuria. These 554 genes were then overlaid on the
sets of genes differentially expressed in human SLE
biopsy specimens (16,17). Two hundred and one genes
were concordantly regulated in the glomeruli and 132 in
the tubulointerstitium of human SLE biopsy specimens,
with 97 concordantly regulated (31 up-regulated and 66
down-regulated) in both compartments (see Supplemen-
tary Table 6A, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38679/abstract). The most highly up-regulated of
these 97 genes were associated with myeloid and lym-
phoid cell infiltration and activation, antigen presenta-
tion, and innate immune processes, including ubiquiti-
nation, nucleic acid exonuclease activity, and type I IFN
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production. UBD (FAT10) was the most highly up-
regulated nonimmune gene.
Because the genes thus identified were domi-
nated by those associated with established nephritis, we
repeated the analysis using only the first 3 groups of the
time series (16-week-old mice, 23-week-old mice without
proteinuria, and 23-week-old mice with proteinuria) and
the 2 remission groups (Supplementary Figure 3B). Of
the top 600 genes in the dominant pattern, 121 were
concordantly regulated in human glomeruli and 119 in
interstitium, with 81 concordantly regulated in both
compartments. Of these 81 genes, 40 (30 up-regulated
and 10 down-regulated) were within the subset of 603
genes that were regulated 1.5 fold during both disease
onset and remission. The most highly up-regulated of
these 40 genes in the human biopsy specimens included
genes involved in innate immunity, such as IFIH1,
CXCL10, and PLAC8 (Onzin), a regulator of proinflam-
matory responses. Other up-regulated genes include
VCAM1; NMI, an IFN- and interleukin-2–induced
signaling molecule; CKLF, a chemoattractant; FGL2, a
prothrombinase induced during inflammation; and
SNAI2, a mediator of epithelial-to-mesenchymal transi-
tion (Supplementary Table 6B).
Confirmation by real-time PCR. Results from
real-time PCR analyses are shown in Supplementary
Table 7 and Supplementary Figure 4, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38679/abstract. There was a
high level of concordance with those genes shown to be
regulated by microarray, but the PCR was more sensitive
and therefore detected expression of some genes not
detected by microarray analysis. Of 166 genes, only 4
(CCL2, CCL5, CD52, and LY86) were regulated 1.5
fold before nephritis onset, reversed with remission
induction, became abnormal again during late remission,
and were also expressed in both human glomeruli and
tubulointerstitium. FCGR, with a similar expression pat-
tern, was up-regulated in human glomeruli (Figure 3A).
A subset of genes displayed a pattern of regula-
tion at proteinuria onset, reversal with complete remis-
sion induction, and re-expression during late remission;
many of these were associated with macrophage activa-
tion. C1qA, ISG20, CTSS, TGFBI (a component of
extracellular matrix), and CYBB (NADPH oxidase 2)
were robust markers of progression toward relapse and
also highly expressed in human biopsy specimens (Fig-
ure 3A). In contrast, TNFRSF12, Serpina3g, Fpr2,
Clec4e, and Grem1 were highly associated with disease
stage in the mouse tissues but were not detected in
Figure 2. Heatmaps of genes representing the mitochondrial signa-
ture (top panel) and the hypoxia, stress/toxicity, and oxidative stress
signature (bottom panel) that are present in self-organizing map
(SOM) cluster 2 and are regulated in mice during late remission of
lupus nephritis. The heatmaps were generated using the SOM module
in MultiExperiment Viewer Application (http://www.tm4.org/). The
top bar in each panel (SOM vector) represents an average of the gene
expression for the corresponding sample. See Figure 1 for other
definitions.
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human biopsy specimens. Genes that were regulated
before proteinuria onset were significantly less likely to
revert to normal during remission than genes that were
regulated after proteinuria onset (P  0.005) (data not
shown).
Up-regulated genes whose expression did not
completely revert to normal at remission included a
subset of chemokines, cytokines, and adhesion mole-
cules, probably reflecting the incomplete disappearance
of lymphoid aggregates, as well as Ubd (FAT10), a
marker of tubular epithelial dysfunction. In addition, the
down-regulation of VEGFA and FGF2 did not reverse
completely with remission induction, suggesting a con-
tinuing defect in angiogenesis (Figure 3B).
We confirmed that several genes related to
mitochondrial dysfunction or metabolic stress, including
NOX4 and COX15, became abnormal late after treat-
ment with CTLA-4Ig/TACI-Ig. In addition, LCN2 and
TIMP1, genes that were up-regulated at proteinuria
onset and reversed with remission induction, were mod-
estly up-regulated late after treatment with CTLA-4Ig/
TACI-Ig before the onset of overt proteinuria.
Finally, we identified a subset of genes whose
expression remained at remission levels even during
late remission. Up-regulated genes with this pattern
included CD14, ANKRD1 (podocyte injury), TGFB,
CXCL9, CXCL10, CXCL11, CXCL16, and CCL9
(chemokines), ICAM1 and VCAM1 (endothelial ac-
tivation), HAVCR1, and C3 (tubular injury), whereas
down-regulated genes included EGF, CLYBL,
DNASE1, and several genes involved in drug detoxifi-
cation (Figure 3C).
Application of these data to a second murine
model. Of 3,759 genes that were regulated in nephritic
versus young NZM2410 mice (17), 2,364 (62.9%) were
reversed after BAFF inhibition (see Supplementary
Table 8, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.
38679/abstract), reflecting improvements in inflamma-
tion, endothelial cell activation, tubular dysfunction,
metabolic stress, and mitochondrial dysfunction. Rever-
sal of nephrin loss suggests that podocyte repair may
occur. Of these genes, 399 were concordantly regulated
in both the glomeruli and tubulointerstitium of SLE
nephritis biopsy specimens; this set of 399 genes was
quite similar to that identified in NZB/NZW mice (see
Supplementary Table 9, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38679/abstract). After BAFF inhibition,
1,395 genes did not reverse, including both proinflam-
matory genes and genes related to mitochondrial dys-
function (data not shown), suggesting that, as in NZB/
NZW mice, immunomodulation may not completely
reverse processes that could contribute to ongoing renal
damage.
Quantitative RT-PCR analyses showed increased
expression of a subset of proinflammatory cytokines and
chemokines in the mice with disease in remission (data
not shown), but this was not associated with clinical
relapse. As in NZB/NZW mice, a cluster of genes was
identified whose expression reversed after remission
induction and remained at remission levels even 33
weeks after BAFF-R-Ig therapy (see Supplementary
Table 10 and Supplementary Figure 5, available on the
Figure 3. Expression of selected genes in (NZB  NZW)F1 mouse kidneys over time, as determined by polymerase chain reaction. A, Genes that
were up-regulated prior to proteinuria onset (solid lines) or at proteinuria onset (broken lines), reverted during remission, and became abnormal
again during relapse and were also expressed in biopsy specimens from the kidneys of patients with systemic lupus erythematosus. B, Genes that were
up-regulated at proteinuria onset and did not revert during remission. C, Genes that were up-regulated at proteinuria onset, reverted at remission,
and remained normal during late remission. All Y all young mice (pooled data from 6-week-old and 16-week-old mice); E Rem early remission;
L Rem  late remission; L Rem C/T  late remission and treatment with CTLA-4Ig and TACI-Ig. See Figure 1 for other definitions.
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Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38679/abstract).
DISCUSSION
Our study identifies sequential molecular events
in the progression and remission of SLE nephritis in
informative mouse models. We show limited expression
of inflammatory mediators during the prenephritic stage
in NZB/NZW mice. In contrast, a major signature of
inflammatory cell infiltration and activation occurs at
the onset of proteinuria. This is accompanied by in-
creased expression of a variety of collagen genes and
evidence of endothelial cell activation, and tubular dam-
age. These changes are associated with glomerular hy-
pertrophy and proliferative changes, and progressive
accumulation of periglomerular and perivascular lym-
phoid aggregates (9).
As glomerular inflammation progresses, compro-
mise of the downstream peritubular blood flow (for
review, see ref. 24) is associated with a signature of
oxidative and metabolic stress, mitochondrial dysfunc-
tion, and tubular damage. In addition, activation of the
peritubular endothelium can induce inflammatory cell
infiltration, particularly of macrophages, into the tubu-
lointerstitium. We show that disease progression is
characterized by continued recruitment of proinflamma-
tory mediators and expression of genes involved in
macrophage activation, alternative complement activa-
tion, prothrombotic tendency, and fibrosis. Importantly,
an unbiased analysis of the sequential microarray data
sets from NZB/NZW mice confirms that there are two
major gene clusters that are dynamically regulated dur-
ing disease onset and remission. One, occurring at
proteinuria onset, identifies the inflammatory compo-
nent of nephritis, and the other, occurring during estab-
lished disease, reflects the metabolic disturbances that
are associated with hypoxia.
Previous studies have described the gene expres-
sion profiles in NZB/NZW (25) and MRL/lpr mouse
kidneys (26), including the effect of preventive treat-
ments (rapamycin and prednisone, respectively). De-
spite the different methods used (e.g., glomeruli laser
microdissection in the case of the MRL/lpr mouse
study), a significant gene overlap (67% and 57%, respec-
tively) was confirmed between our 16-week-old mice
versus 36–40-week-old mice data set and the genes that
were regulated in mice with established nephritis com-
pared to young mice in those studies.
We further show here that remission induced by
costimulatory blockade or BAFF inhibition (9,11) is
associated with the reversal of much of the inflammatory
signature that accompanies proteinuria onset. Impor-
tantly, however, in NZB/NZW mice, the mitochondrial
and metabolic signature recurs before the reappearance
of proteinuria, perhaps reflecting an increased propen-
sity to hypoxia conferred by the initial tissue insult. In
NZM2410 mice, reversal of this signature is incomplete
despite histologic remission. In these mice a subset of
inflammatory markers and inflammatory cells accumu-
lates during long-lasting remission following BAFF in-
hibition, but this is not sufficient for clinical relapse. A
similar checkpoint has been described in BAFF-
deficient NZM2328 mice and in mice congenic for an
NZM-derived gene locus that develop glomerular pa-
thology and lymphoid infiltrates but do not progress to
renal failure (15,27). These data show that renal decline
does not inevitably follow renal inflammatory cell infil-
tration. Rather, our molecular data suggest that podo-
cyte damage, renal tubular dysfunction, endothelial cell
activation, and tissue remodeling are the functional
features associated with the clinical onset of proteinuria
and consequent renal failure.
Our study gave us an opportunity to identify
transcriptional profiles characteristic of each specific
disease stage, with the potential to serve as biomarker
candidates. Using PCR we identified CCL2, CCL5,
LY86, CD52, and FCGR3 as genes that were up-
regulated in prenephritic kidneys, fluctuated with early
and late remission, and were also highly expressed in
human SLE nephritis biopsy specimens. Of these, in-
creasing urinary CCL2 (monocyte chemotactic protein
1) is currently the most promising biomarker for disease
flare (28,29), whereas failure to normalize urinary CCL5
(RANTES) during remission is associated with an in-
creased risk of subsequent flare (30). LY86 (MD-1) is
expressed by plasma cells and renal macrophages; inter-
estingly, serum levels of soluble LY86 correlate with
disease progression in MRL/lpr mice (31). CD52 and
FCGR3 are markers for infiltrating renal cells. Surpris-
ingly, TNFRSF12 (which encodes for the TWEAK
receptor), which is up-regulated in prenephritic mice
and is an excellent biomarker for remission and progres-
sion, was not detected in our human lupus biopsy
specimens. Nevertheless, a previous study using real-
time PCR detected TNFRSF12 mRNA in lupus glom-
eruli and interstitium (32).
Genes that are regulated at proteinuria onset,
reverse with remission induction, and become abnormal
again during late remission may be useful biomarkers of
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impending flare or of failure to respond to therapy. We
identified several such genes that are associated with
macrophage activation. Of those that were also identi-
fied in human kidneys, C1q components are of interest
because these are produced mostly by tissue macro-
phages and may therefore reflect macrophage/DC infil-
tration and/or activation. Importantly, antibodies to C1q
are associated with lupus nephritis, and may amplify
tissue damage (33). How C1q modulates local macro-
phage function in the setting of inflammation is not
currently known.
To identify genes whose expression most tightly
correlated with disease stage, we used an unbiased
approach. Using an NZB/NZW data set that included
the prenephritic stage, new-onset proteinuria, and re-
mission, we identified 41 such genes that were also
expressed in human SLE biopsy specimens. These in-
clude the procoagulant FGL2 and PLAC8 (which en-
codes onzin), a molecule required for antibacterial and
inflammatory responses (34). Two additional genes,
CXCL10 and VCAM1, encode soluble proteins that
have already been identified as potential urinary bio-
markers for human lupus nephritis (5,35,36). In the
human biopsy specimens, the expression of CXCL10 was
coupled with expression of its inducing protein IFIH1
(MDA5), an IFN-inducible gene that is highly expressed
in the glomeruli of SLE nephritis patients (37). Urinary
levels of VCAM1 are strongly associated with renal
disease activity in mouse and human lupus nephritis in
cross-sectional studies (for review, see ref. 35). FGL2
and PLAC8 were regulated at proteinuria onset, re-
verted with remission induction, and were expressed
again during late remission, whereas IFIH1, VCAM1,
and CXCL10 remained normal during late remission.
When the whole series of NZB/NZW samples
was included in an unbiased analysis of genes regulated
with disease stage, 97 genes were identified that were
also expressed in both compartments of human SLE
biopsy specimens. These included genes involved in
innate immunity, many of which are IFN inducible,
confirming the sensitivity of genes involved in this
pathway to changes in disease activity. Notably, this gene
set included LCN2, a marker of proximal tubular dam-
age. While initial longitudinal studies suggested that
increasing urine levels of lipocalin 2 (LCN-2) could
predict a flare of SLE nephritis, especially in children
(38,39), a recent large longitudinal study in adults failed
to reproduce these results (40). Our data suggest that
LCN-2 is a relatively late marker of SLE nephritis that is
highly responsive to remission induction. Indeed, LCN2
was not expressed in the human lupus biopsy specimens,
most of which were harvested from patients who had
already begun glucocorticoid therapy (17). We also
found among this gene set genes whose expression was
detected only in mice with proteinuria and remained
normal even during late remission. Although such genes
may not be sensitive markers of an impending renal
flare, they may be of potential use in following up a
response to therapy.
Future studies will determine whether the genes
we have identified herein can serve as biomarkers for
flares or responses to therapy or whether they will help
distinguish active disease from chronic changes. While
not all of the gene products of our biomarker gene set
are soluble, methodology for performing expression,
proteomic, or metabolic analysis of urine cells is con-
stantly improving and could be used to test sequential
expression of some of the other highly expressed genes
or pathways.
Given the current lack of sufficiently effective
therapy for lupus nephritis and the unacceptably high
rate of disease relapse, one important goal of these
studies was to identify pathways and molecules that
suggest potential therapeutic targets. While lupus ne-
phritis is classically treated with immunosuppressive
therapies, less attention has been paid to the correction
of metabolic inefficiency and cellular stress. Multiple
strategies to achieve this have been tested in animal
models (41,42). In addition, our study has identified
several understudied molecules that are tightly regulated
with disease stage, highly expressed in the human biopsy
specimens, and whose role can be further explored in the
appropriate murine models. These include Laptm5, a
positive regulator of macrophage proinflammatory cyto-
kine production (43), Plac8 (onzin), and ubiquitin D
(FAT10), a proteasome binding protein that promotes
tubulointerstitial inflammation in kidney diseases via
NF-B activation (44,45).
In conclusion, our studies show that limited renal
chemokine and cytokine production occurs during the
prenephritic phase, whereas inflammatory events esca-
late at or just before proteinuria onset. This is followed
by hypoxia and metabolic stress, and finally by tubular
and endothelial dysfunction. Regimens that include co-
stimulatory blockade and BAFF inhibition reverse in-
flammatory events, but progression toward relapse is
associated with recurrence of inflammation, cellular
stress, and mitochondrial dysfunction. Not all molecular
abnormalities are reversed by remission induction ther-
apies, perhaps increasing the sensitivity of the kidney to
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hypoxia during flare and contributing to progressive
renal damage even during periods of quiescence. In
contrast, some molecules maintain their normal expres-
sion profile even during the late stages of remission. We
show, in sum, that there are several checkpoints along
the path to renal failure in lupus nephritis that are
associated with renal molecular changes and expression
of stage-specific biomarkers, some of which can now be
tested in humans.
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